TABLE 2.
Reproducibility data generated at the six study sites (phase II) during AST of 20 strains of M. tuberculosis
| Drug | Strain categorya (no. of strains) | Test system | Inhibitory concn (μg/ml) | No. of cultures at site:
|
Total no. of cultures | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |||||
| Capreomycin | S (14) | BACTEC 460 | ≤1.25 | 14 | 13 | 14 | 11 | 7 | 13 | 72 |
| 2.5 | 0 | 1 | 0 | 2 | 7 | 0 | 10 | |||
| 5 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | |||
| Middlebrook 7H10 | ≤10.0 | 13 | 13 | 12c | 14 | 14 | 12 | 78 | ||
| R (6) | BACTEC 460 | >5.0 | 6 | 6 | 6 | 6 | 6 | 6 | 36 | |
| Middlebrook 7H10 | >10.0 | 6 | 6 | 1 | 6 | 0c | 6 | 25 | ||
| Cycloserine | S (20) | BACTEC 460 | ≤75 | 20 | 20 | 18 | 17 | 14 | —b | 89 |
| 100 | 0 | 0 | 1 | 3 | 5 | — | 9 | |||
| 200 | 0 | 0 | 1 | 0 | 1 | — | 2 | |||
| Middlebrook 7H10 | ≤30 | 19 | 20 | 18 | 18 | 16 | — | 91 | ||
| Ethionamide | S (10) | BACTEC 460 | ≤0.625 | 6 | 6 | 6 | 3 | 3 | 5 | 29 |
| 1.25 | 3 | 4 | 4 | 6 | 6 | 5 | 28 | |||
| 2.5 | 1 | 0 | 0 | 1 | 1 | 0 | 3 | |||
| Middlebrook 7H10 | ≤5.0 | 7 | 9 | 10 | 10 | 10 | 9 | 55 | ||
| R (10) | BACTEC 460 | ≤0.625 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | |
| 1.25 | 1 | 2 | 1 | 1 | 1 | 0 | 6 | |||
| 2.5 | 2 | 2 | 1 | 2 | 2 | 1 | 10 | |||
| >2.5 | 7 | 6 | 8 | 7 | 6 | 9 | 43 | |||
| Middlebrook 7H10 | ≥5.0 | 10 | 9 | 2c | 10 | 4c | 2 | 37 | ||
| Kanamycin | S (11) | BACTEC 460 | ≤1.25 | 8 | 7 | 7 | 6 | 7 | 8 | 43 |
| 2.5 | 3 | 4 | 4 | 5 | 4 | 3 | 23 | |||
| Middlebrook 7H10 | ≤5.0 | 11 | 11 | 11 | 11 | 11 | 10 | 65 | ||
| R (9) | BACTEC 460 | ≤1.25 | 0 | 0 | 1 | 0 | 1 | 3 | 1 | |
| 2.5 | 1 | 1 | 0 | 1 | 0 | 0 | 3 | |||
| 5 | 8 | 8 | 8 | 8 | 8 | 8 | 48 | |||
| Middlebrook 7H10 | ≥5.0 | 9 | 9 | 9 | 9 | 7 | 9 | 52 | ||
| Amikacin | S (12) | BACTEC 460 | ≤0.5 | 12 | 12 | 11c | 12 | 12 | 12 | 71 |
| Middlebrook 7H10 | ≤2.0 | 11 | 11 | 11 | 10 | 12 | 12 | 67 | ||
| 4.0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | |||
| >4.0 | 1 | 1 | 1 | 1 | 0 | 0 | 4 | |||
| R (8) | BACTEC 460 | >2.0 | 8 | 8 | 8 | 8 | 8 | 8 | 48 | |
| Middlebrook 7H10 | >4.0 | 8 | 8 | 8 | 8 | 7c | 8 | 47 | ||
| Clofazimine | S (19) | BACTEC 460 | ≤0.125 | 13 | 19 | 18 | 19 | 18 | 19 | 106 |
| 0.25 | 6 | 0 | 1 | 0 | 1 | 0 | 8 | |||
| Middlebrook 7H10 | ≤0.5 | 19 | 19 | 18c | 19 | 18c | 17 | 110 | ||
| 1 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | |||
| R (1) | BACTEC 460 | ≤0.125 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | |
| 0.5 | 0 | 1 | 1 | 0 | 1 | 0 | 3 | |||
| >0.5 | 1 | 0 | 0 | 0 | 0 | 1 | 2 | |||
| Middlebrook 7H10 | ≤0.5 | 0 | 0 | 1 | 1 | 1 | 0 | 3 | ||
| 1.0 | 1 | 1 | 0 | 0 | 0 | 0 | 2 | |||
| >1.0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | |||
| Ofloxacin | S (19) | BACTEC 460 | ≤1.0 | 16 | 15 | 14 | 16 | 18 | 15 | 94 |
| 2.0 | 3 | 4 | 5 | 3 | 1 | 4 | 20 | |||
| Middlebrook 7H10 | ≤1.0 | 18 | 19 | 17c | 14 | 18c | 12 | 98 | ||
| 2.0 | 1 | 0 | 1 | 5 | 0 | 7 | 14 | |||
| R (1) | BACTEC 460 | 4.0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | |
| >4.0 | 0 | 1 | 1 | 1 | 1 | 1 | 5 | |||
| Middlebrook 7H10 | >4.0 | 1 | 1 | 1 | 1 | 1 | 1 | 6 | ||
| Rifabutin | S (7) | BACTEC 460 | ≤0.5 | 6 | 6 | 6 | 7 | 7 | 7 | 39 |
| 1.0 | 1 | 1 | 1 | 0 | 0 | 0 | 3 | |||
| Middlebrook 7H10 | ≤0.5 | 7 | 7 | 7 | 7 | 7 | 7 | 42 | ||
| R (13) | BACTEC 460 | 1.0 | 1 | 1 | 0 | 0 | 1 | 1 | 4 | |
| 2.0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | |||
| >2.0 | 12 | 12 | 12 | 12 | 12 | 12 | 72 | |||
| Middlebrook 7H10 | ≤0.5 | 1 | 1 | 0 | 0 | 1 | 1 | 4 | ||
| 1.0 | 0 | 0 | 0 | 1 | 2 | 0 | 3 | |||
| 2.0 | 0 | 0 | 3 | 0 | 2 | 0 | 5 | |||
| >2.0 | 12 | 12 | 9c | 12 | 5c | 12 | 62 | |||
S, susceptible; R, resistant.
Site 6 was excluded (see Results).
Results of some susceptibility tests are missing.